Denali Therapeutics falls as ALS drug fails to meet main goal in mid-stage study
Denali-Sanofi's ALS drug fails to meet main goal of mid-stage trial (updated)
Denali-Sanofi's ALS drug fails to meet main goal of mid-stage trial
Brief: Denali Therapeutics Expects Enrollment To Be Completed In Late-Stage Trials For MPS II And ALS IN 2024
Denali Therapeutics Inc expected to post a loss of 80 cents a share - Earnings Preview
Jefferies says Denali to benefit by data from Roche's Alzheimer drug delivery system
Brief: Denali Therapeutics Announces New Interim Data From Phase 1/2 Study Of Dnl310
Denali Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Denali Therapeutics Q2 EPS USD 1.3
Denali Therapeutics Inc expected to post a loss of 68 cents a share - Earnings Preview
Pfizer, Flagship Pioneering to invest $100 mln in drug discovery (updated)
Pfizer, Flagship Pioneering to invest $100 mln for drug discovery
Brief: Denali Therapeutics Inc Says Additional Interim Data From DNL310 Phase 1/2 Study Will Be Presented at SSIEM Symposium In August
Denali falls on plans to revise development of Parkinson's disease treatment program
Brief: Denali Therapeutics and Biogen To Revise Clinical Development Program For BIIB122, Being Developed As Treatment Of Parkinson’s Disease
Brief: Denali Therapeutics Reports First Quarter 2023 Financial Results And Business Highlights
Denali Therapeutics Inc expected to post a loss of 70 cents a share - Earnings Preview
Brief: Biogen Exercises Option With Denali To Develop And Commercialize Antibody Transport Vehicle Program Targeting Amyloid Beta
U.S. STOCKS ON THE MOVE-SiriusPoint, Nutex Health, Barrick Gold